1. Deatona, Christi, Froelicher, Erika Sivarajan, Wuc, Lai Har, Hod, Camille, Shishani, Kawkab, & Jaarsmaf, Tiny. (2011). The global burden of cardiovascular disease. European Journal of Cardiovascular Nursing,10(2), S5–S13.
2. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
3. Rohini, A., Agrawal, N., Koyani, C. N., & Singh, R. (2010). Molecular targets and regulators of cardiac hypertrophy. Pharmacological Research,61(4), 269–280.
4. Nadal-Ginard, B., Kajstura, J., Leri, A., & Anversa, P. (2003). Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circulation Research,92(2), 139–150.
5. Zhang, Y., Xu, J., Long, Z., Wang, C., Wang, L., Sun, P., et al. (2016). Hydrogen (H2) inhibits isoproterenol-induced cardiac hypertrophy via antioxidative pathways. Frontiers in Pharmacology,7, 392.